Table 3.
Summary and disaggregated cost results for three formulations of Eligard® in nine European countries over 12 months
| Austria | Belgium | Czech Republic | Hungary | Italy | Lativa | Netherlands | Poland | Portugal | |
|---|---|---|---|---|---|---|---|---|---|
| Direct costs* (95% CI) | |||||||||
| 1 M | 4361 (3698–5107) | 1982 (1887–2078) | 1987 (1937–2036) | 1364 (1351–1376) | 2796 (2664–2919) | 1961 (1882–2023) | 3665 (3421–3905) | 1255 (1232–1284) | 3236 (3073–3407) |
| 3 M | 2411 (2167–2705) | 1084 (1049–1121) | 1529 (1507–1551) | 1211 (1206–1218) | 1949 (1895–2000) | 1587 (1558–1616) | 2156 (2065–2254) | 1072 (1060–1083) | 2181 (2112–2255) |
| 6 M | 1784 (1663–1920) | 788 (771–805) | 1446 (1435–1455) | 1182 (1179–1184) | 1741 (1716–1765) | 1110 (1093–1122) | 1661 (1617–1704) | 1014 (1010–1020) | 1839 (1806–1871) |
| Aggregated costs† (95% CI) | |||||||||
| 1 M | 4502 (3893–5157) | 2136 (2030–2242) | 2042 (1992–2093) | 1437 (1418–1456) | 2929 (2817–3054) | 2116 (2038–2174) | 3851 (3586–4070) | 1305 (1280–1334) | 3321 (3179–3533) |
| 3 M | 2462 (2259–2711) | 1140 (1098–1179) | 1551 (1530–1572) | 1240 (1233–1249) | 2003 (1952–2060) | 1649 (1615–1675) | 2224 (2128–2306) | 1091 (1079–1108) | 2214 (2161–2305) |
| 6 M | 1809 (1698–1932) | 815 (796–834) | 1456 (1447–1466) | 1196 (1192–1199) | 1767 (1745–1790) | 1140 (1125–1152) | 1694 (1648–1734) | 1024 (1019–1030) | 1855 (1824–1896) |
| Cost of Eligard | |||||||||
| 1 M | 1282 | 1148 | 1585 | 1252 | 1797 | 1454 | 1282 | 981 | 1778 |
| 3 M | 1282 | 778 | 1369 | 1167 | 1550 | 1384 | 1282 | 962 | 1598 |
| 6 M | 1238 | 640 | 1369 | 1160 | 1550 | 1013 | 1238 | 962 | 1559 |
| Cost of visits (number of visits) | |||||||||
| 1 M | 3080 (12.0) | 834 (12.0) | 1094 (12.0) | 112 (12.0) | 998 (12.0) | 507 (12.0) | 2384 (12.0) | 274 (12.0) | 1457 (12.0) |
| 3 M | 1129 (4.4) | 306 (4.4) | 438 (4.8) | 45 (4.8) | 399 (4.4) | 203 (4.8) | 874 (4.4) | 110 (4.8) | 583 (4.8) |
| 6 M | 545 (2.1) | 148 (2.1) | 210 (2.3) | 21 (2.3) | 191 (2.1) | 97 (2.3) | 422 (2.1) | 53 (2.3) | 279 (2.3) |
| Nonmedical costs§ | |||||||||
| 1 M | 68.40 | 52.80 | 46.56 | 65.10 | 48.00 | 135.24 | 84.00 | 25.95 | 50.40 |
| 3 M | 25.08 | 19.36 | 18.62 | 26.04 | 19.20 | 54.10 | 30.80 | 10.38 | 20.16 |
| 6 M | 12.11 | 9.35 | 8.92 | 12.48 | 9.20 | 25.92 | 14.88 | 4.97 | 9.66 |
| Indirect cost# | |||||||||
| 1 M | 71.43 | 101.09 | 8.87 | 7.80 | 85.71 | 20.13 | 101.74 | 23.79 | 34.64 |
| 3 M | 26.19 | 37.07 | 3.55 | 3.12 | 34.29 | 8.05 | 37.31 | 9.52 | 13.86 |
| 6 M | 12.65 | 17.90 | 1.70 | 1.50 | 16.43 | 3.86 | 18.02 | 4.56 | 6.64 |
Notes: Uncertainty intervals refer to results from the probabilistic sensitivity analysis.
*
Medical costs borne by the payer;
†
direct plus indirect and nonmedical costs;
§
public transport;
#
productivity loss based on minimum wage and accounting for retirement status. As adverse event costs were 0 in most cases and did not exceed €0.70 for any formulation in any country, these have been omitted from the table. Registered trademarks of Eligard®, Sanofi S.A./Tolmar Therapeutics Inc (Fort Collins, CO, USA).
Abbreviations: CI, confidence interval; 1 M, 1-monthly; 3 M, 3-monthly; 6 M, 6-monthly.